Tag Archives: CELG

stock market best stocks

In both bull and bear markets, it’s never too late to buy stocks. Picking the right stocks to buy, of course, is the biggest challenge. For investors looking to buy stocks today, here are three that look enticing.

Image source: Getty Images.

Buying stocks

Why buy stocks in the first place?

By buying stocks, investors position themselves to not only save money but to potentially watch their money grow, whether it’s through share price appreciation, dividends, or both. Yes, buying stocks is a risk. But it is also an opportunity. It gives investors a chance to earn excellent returns.

Finally, investors should keep in mind that there is never a “right” time to buy stocks. Since attempting to time when the market will rise or fall has proved to be impossible for anyone to do consistently, the best thing investors can do is maximize their time in the market, giving themselves the greatest opportunity to watch their portfolios’ value rise over time.

stock market best stocks: Becton, Dickinson and Company(BDX)

Advisors’ Opinion:

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Thursday was Becton Dickinson and Co. (NYSE: BDX) which traded down 4.4% at $177.19. The stocks 52-week range is $157.60 to $186.40. Volume was 9.3 million versus the daily average of 833,000 shares.

  • [By Ben Levisohn]

    Becton Dickinson (BDX) tumbled to the bottom of the S&P 500 today after agreeing to pay $24 billion for C.R. Bard (BCR).

    Agence France-Presse/Getty Images

    Becton Dickinsondropped 4.4% to $177.07, while the S&P 500 rose 1.1% to 2,374.15. C.R. Bard jumped 20% to $302.41, making it the best performing stock in the S&P 500.

    Leerink’sRichard Newitter andRavi Misra argue that “growth doesn’t come cheap.” They explain:

    We had expected BDX’s M&A engine would eventually resume as the company moved into its third year post the 2015 CareFusion (CFN) acquisition; however, we do think the expectation was for tuck-in or mid-sized type transactions. This transaction is certainly on the bigger side, and will mark the largest in BDX’s history just as BDX wraps up year 2 post the CFN integration. Naturally this could raise some questions as to whether mgmt is “biting off more than it can chew.” But, size (and the hefty price tag) aside, the rationale is not entirely out of left field in our view. BCR will benefit BDX through a higher top-line & GM profile and provides several fast-growing product offerings in underpenetrated markets (i.e. PICCs, Lutonix/Drug Coated Balloons, targeted temperature mgmt). BCR’s Foley catheters and PICC products should complement BDX’s portfolio & strategy aimed at offering a single complete end- to-end medication managem ent & safety solution to hospitals. Also, BCR’s emerging markets (EM) growth is accelerating, which should help BDX’s EM division, which has been experiencing slowing growth in recent years.

    Becton Dickinson’s market capitalization fell to $37.7 billion today from $39.4 billion on Friday. It reported net income of $976 million on sales of $12.5 billion in 2016.

  • [By Lisa Levin]

    C R Bard Inc (NYSE: BCR) shares were also up, gaining 20 percent to $304.08 after Becton Dickinson and Co (NYSE: BDX) announced plans to acquire the company for $24 billion.

  • [By Money Morning News Team]

    Becton Dickinson and Co. (NYSE: BDX) is a New Jersey-based developer and manufacturer of medical devices. The company’s products include various types of needles and syringe systems, infusion therapy products, and blood collection products. Its devices are used by healthcare organizations for research, laboratory operations, and health-related safety.

stock market best stocks: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By Keith Speights]

    Juno’s relationship withCelgene(NASDAQ:CELG) is another plus. In April of last year, the big biotech exercised its option for marketing rights to Juno’s CD19 program outside of North American and China. This program at the time included JCAR014, JCAR015, and early stage candidate JCAR017. Celgene was involved in the decision to throw in the towel on JCAR015.

  • [By WWW.THESTREET.COM]

    Celgene (CELG) : “Celgene’s a buy, I think it’s terrific.”

    Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener.

  • [By Keith Speights]

    Research and development is the lifeblood of biotech companies. The potential for new drugs also serves as a primary factor driving biotech stocks higher and higher. That’s been the case for Celgene (NASDAQ:CELG), Ionis Pharmaceuticals (NASDAQ:IONS), and Ligand Pharmaceuticals (NASDAQ:LGND).

  • [By Todd Campbell]

    The company is also going to continue early stage research into its CAR-T program, including its work on bb2121, a BCMA-targeting therapy that’s being developed with Celgene (NASDAQ:CELG) for multiple myeloma.

  • [By Todd Shriber, ETF Professor]

    Several big-name biotech companies step into the earnings confessional starting in the middle of the week, with Amgen, Inc. (NASDAQ: AMGN), Anthem Inc (NYSE: ANTM), and Celgene Corporation (NASDAQ: CELG) among the companies in play. That could bring opportunity with the  Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU) and the Direxion Daily S&P Biotech Bear 3X Shares (NYSE: LABD).

  • [By Peter Graham]

    A long term performance shows shares of small cap cancer stocks Juno Therapeutics and Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) underperforming whileKite Pharma Inc (NASDAQ: KITE)andlarge cap Celgene Corporation (NASDAQ: CELG) have performed better:

stock market best stocks: Zynga Inc.(ZNGA)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    What could have gone wrong? Cramer said investors only need to remember the IPOs of Facebook (FB) , Twitter (TWTR) , Groupon (GRPN) and Zynga (ZNGA) . All of these IPOs made the markets look fragile and, yes, rigged. But today, the market avoided four major pitfalls.

  • [By Shanthi Rexaline]

    Most tech companies opt to have the dual class structure with the primary motive of retaining voting control. Facebook Inc (NASDAQ: FB), Zynga Inc (NASDAQ: ZNGA), Groupon Inc (NASDAQ: GRPN) and Box Inc (NYSE: BOX) are a few companies who went the dual class stock structure way.

  • [By Javier Hasse]

    For instance, in his previous startup, Vostu (often dubbed the Zynga Inc (NASDAQ: ZNGA) of Latin America), Recchia had to open an office in the U.S. in order to access top-notch talent in business analytics.

stock market best stocks: Madison Square Garden Inc.(MSG)

Advisors’ Opinion:

  • [By Monica Gerson]

    Madison Square Garden Co (NYSE: MSG) is estimated to report a quarterly loss at $0.34 per share on revenue of $325.53 million.

    Gogo Inc (NASDAQ: GOGO) is projected to report a quarterly loss at $0.42 per share on revenue of $137.58 million.

  • [By Ian Wyatt, Publisher & Chief Investment Strategist, Wyatt Investment Research]

    Meanwhile, Mark Boyar, of The Boyar Value Fund, recommends another household name: Madison Square Garden (MSG). He thinks the Dolan family could take the company private.

stock market best stocks: KeyCorp(KEY)

Advisors’ Opinion:

  • [By Ben Levisohn]

    We believe investors should continue to own three types of bank stocks: “Return of Capital (RC) Stocks”, “Risk On (RO) Stocks”, and “Multiple Revaluation (MR) Stocks.” RC stocks include M&T Bank (MTB), PNC Financial Services Group (PNC), and SunTrust Banks (STI); RO stocks include Bank of America, Popular (BPOP), Citigroup, JPMorgan, and KeyCorp (KEY); and MR stocks include BB&T (BBT) and PNC Financial Services Group (PNC).

  • [By WWW.THESTREET.COM]

    But then there was good news from rail transport company CSX (CSX ) , which saw growth in every one of its business lines. Foot Locker (FL) also surprised to the upside, sending shares up a quick 5.3%. Cramer fave and Action Alerts PLUS holding KeyCorp (KEY) also delivered, as did paint maker Sherwin-Williams (SHW) .

  • [By WWW.THESTREET.COM]

    On the show’s “Lightning Round” segment, Jim Cramer was bullish on Penn National Gaming (PENN) , KeyCorp (KEY) and TherapeuticsMD (TXMD) .

    Quiet Breakups

  • [By Craig Jones]

    On CNBC's Fast Money Halftime Report, Jon Najarian said he noticed big options volume in the December weekly, 18 strike calls in KeyCorp (NYSE: KEY). He decided to follow the trade and he is going to hold the position for 1 to 2 days.

good stocks to buy

Europes economy was hobbling even before Britain voted to go its own way last June. Now, the eurozone may have even less spring in its step. Estimates for economic growth and corporate profits in the region have been sliding. Although some countries may fare well in this climate, it may not be the best time to invest in an exchange-traded fund that covers wide swaths of stocks across the pond.

At a Glance: The Kiplinger ETF 20

Thats why were removing WisdomTree Europe Hedged Equity (HEDJ) from the Kiplinger ETF 20. Over the past year, the fund posted a modest loss of 1.4%. That crushed rivals such as iShares Core Europe ETF (IEUR), which lost 6.1%, largely because the WisdomTree fund hedges its exposure to the euro (which has weakened against the dollar, making stocks priced in euros worth less when converted to greenbacks). But a weak euro isnt reason enough to keep the ETF, partly because were not convinced that the euro will continue to slide. We see better opportunities in funds that arent as closely tied to Europes fortunes.

good stocks to buy: BioScrip, Inc.(BIOS)

Advisors’ Opinion:

  • [By Chris Lange]

    BioScrip, Inc. (NASDAQ: BIOS) saw its shares make a solid gain on Tuesday after another analyst issued a positive rating on the stock. Lake Street Capital initiated its coverage with a Buy rating and a $4.50 price target. This is implying an upside of over 300% from the previous closing price of $1.04.

  • [By Chris Lange]

    On Tuesday, BioScrip Inc. (NASDAQ: BIOS) reported third-quarter financial results before the markets opened. The company said that it had a net loss of $0.09 per share and $224.5 million in revenues. The consensus estimates from Thomson Reuters had called for a net loss of $0.05 per share and revenues of $223.26 million. The same period of last year reportedly EPS of had $0.04 and $247.22 million in revenues.

good stocks to buy: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By Keith Speights]

    Smart investors will be ready to take advantage of a market pullback, whenever it comes and offers discount prices on great stocks. Three drug stocks appear to be excellent choices to buy on a dip: AbbVie (NYSE:ABBV), Allergan (NYSE:AGN), and Celgene (NASDAQ:CELG). Here’s why.

  • [By JACK HOUGH]

    Celgene’s main risk is a little like AMC’s zombies. It will generate more than 60% of its revenue this year from a single medicine called Revlimid, used primarily to treat a type of cancer called multiple myeloma. But Revlimid is gaining regulatory approval for an expanding number of uses. It has plenty of growth potential overseas, and shows promise in combination therapies. And it has more than a decade of remaining patent protection. Analysts predict double-digit yearly revenue growth for Revlimid through the end of the decade.

    By then, Celgene is expected to have four drugs with yearly sales in the billions of dollars, versus just Revlimid today. And a robust pipeline of medicines in development provides ample opportunity for new successes. Management has set a goal of $21 billion in yearly revenue by 2020, up from a projected $9.2 billion this year. If it’s successful, two things are likely to happen. First, Revlimid’s contribution is likely to drop below half of revenue by then. Second, earnings per share could more than double, as Celgene’s growing size offers better leverage on its research and marketing expenses. Shares sell for 22 times this year’s earnings consensus—inexpensive considering the growth outlook.  

  • [By WWW.THESTREET.COM]

    Originally published Nov. 17 at 3:41 p.m. EDT

    The consideration of the contrary has been a theme all week. And here in ” Don’t Run With the Crowd: Embrace the Contrary.”   Miami madness (of a real estate kind)   Mark Grant is scared by our currency’s strength.   Danielle on scenarios.   Boockvar to subscriber Bad Golfer!   JC Penney ( JCP) short puts–a 100% win. (Shorting options frequently ends differently!)   Just say no to closed-end muni-bond funds.   DRYS is all wet.   Could iPhone manufacturing be coming back home?   On inflation breakevens–a picture that speaks volumes.   The market moved higher from the “get go”–in large measure it seems to be a response to the better economic data this morning.   At 3 p.m. stocks were near the day’s highs.   I shorted The Cisco Kid last night. Sticking with this short rental. I added to my ProShares UltraShort S&P500 ETF ( SDS) long (growing ever larger). My net short exposure–is now between small and medium-sized at the close. The US. dollar, as discussed above, continued to rip higher against the euro. I am concerned. Mark Grant is concerned. The market is not concerned. The price of crude oil (down $0.20) settled lower after yesterday’s robust gains. Gold fell $9 as it continues to break down–closing in on $1,200. Ag commodities: wheat up $0.07, corn up $0.04, soybeans up $0.05 and oats up $0.02. Lumber up $7 following the big housing number this morning. Bonds schmeissed . .. iShares Barclays 2

  • [By Todd Campbell]

    A new and highly anticipated study byCelgene Corp. (NASDAQ:CELG) shows that its promising multiple sclerosis drug could soon reshape the $19 billion multiple sclerosis market. On Friday, management reported that ozanimod met its primary endpoint for reducing MS relapses better than Biogen Inc.’s (NASDAQ:BIIB) Avonex, and importantly, it did so without any new safety risks.

  • [By WWW.THESTREET.COM]

    Sometimes you just want to keep a list of stocks that act too well. At the top of the list? Celgene (CELG) . This company had a very good quarter with lots of growth but has been stuck in a range forever. Now it is back to its old self, unlike the other major biotechs, and it’s been soaring. Just plain bothersome not to know.

good stocks to buy: Radient Technologies (RTI)

Advisors’ Opinion:

  • [By Matthew Briar]

    At first glance, a new set of rules from the Drug Enforcement Agency unveiled in the middle of December looked like it posed a problem for cannabis-newcomer Radient Technologies Inc (CVE:RTI). By assigning a controlled substances code number to ‘marijuana extract,’ simultaneously distinguishing (and acknowledging the differences of marijuana, hemp and their derivatives as Schedule I substances. As the ruling’s language explained, “This code number will allow DEA and DEA-registered entities to track quantities of this material separately from quantities of marihuana. This, in turn, will aid in complying with relevant treaty provisions.”

    It presents something of an uncertainty, as it was not clear of the DEA also meant hemp and cannabis extracts when it used the term ‘marijuana extract.’ After all, the Drug Enforcement Agency has thus far done a poor job of distinguishing between hemp and marijuana, but has generally erred on the side of grouping everything as marijuana…. even if it didn’t cause a ‘high,’ and even if it did provide a medical benefit. If that was indeed the case, Radient Technologies may well be a non-starter in its quest to get into the cannabis business.

    No need to worry. Though it took weeks to get some much-needed clarification, the DEA has finally explained what it was saying two months ago. Indeed, the new ruling may actually help the medical marijuana — cannabis — along. DEA spokesman Russ Baer said in an e-mail to The Cannabist, “(The rule change) recognizes that there is a potential medical benefit to some of the cannabinoids.”

    Some still worry the wording of the law essentially, even if unintentionally, puts cannabinoids (or CBD) under the purveyance of the DEA; it’s currently not. Even so, if nothing else the ruling has the government moving towards clarity, after acknowledging CBD — the healthy version of the cannabis, and not the one that gets you high — has medical value. The next step is clarifying ho

  • [By Matthew Briar]

    There’s an old business adage…. it’s not so much what you know, but who you know. If that’ s truly the case (and it is), then shareholders in Radient Technologies Inc (CVE:RTI) should be elated. The newest member of the Board of Directors that not already knows a lot of the right people, but has pretty much done all of things Radient would like to accomplish in the near future. That is, he was on the board for another ingredient and chemical company that was eventually acquired, but he also holds a masters degree in engineering. He can do it all, understanding the art and science of the business.

    It’s yet another reason for RTI investors to be enthused.

    Radient Technologies isn’t exactly a new company, but it’s relative notoriety is a fairly new phenomenon.

    The organization, in simplest terms, has developed an ingredient-extraction process called microwave assisted processing, or “MAP,” for short. As the name implies, the use of radio microwaves helps the extraction process along.

    Using its patented MAP process, Radient is able to selectively deposit microwave energy into a biomass (source material) and heat the target elements while leaving other materials in the mix unaltered. The near-instantaneous “in-core” heating that occurs creates pressure which drives out the targeting ingredient or component much faster than more conventional extraction methods. In fact, the pressure-driven process outperforms the conventional extraction on pretty much every front. That is, the technique reduces the extraction time from hours to minutes, delivers a higher active ingredient purity, increases the recovery of actives from often scarce biomass, and uses much less solvent and energy than the more typical approach.

    The technique can, and already has, created natural ingredients for global customers across a range of industries, including food and beverage, nutrition, supplements, pharmaceuticals and cosmetics.

    The company’

  • [By Bryan Murphy]

    It’s been a long time in the coming, but there’s no denying the tipping point has been reached — cannabinoids are the foundation for a whole new kind of medicine. And, the work-to-date turning cannabis into pharmaceuticals has been very encouraging.

    Problem: While the premise of cannabinoids as drugs has been validated, the science of creating large quantities of pure cannabinoids remains more ineffective than effective. Radient Technologies Inc (CVE:RTI) is about the change that, leveraging a means of extracting a lot of cannabinoid material from a source, and ensuring the highest-level of purity and quality.

    Radient Technologies manufactures natural ingredients for global customers across a range of industries, including food and beverage, nutrition, supplements, pharmaceuticals and cosmetics. Using a proprietary, patented technology, Radient’s products are superior in quality and purity while manufactured at a significantly lower cost than other methods thanks to superior yields and efficiency.

    To fully appreciate the science Radient has developed, however, one must understand the alternative methods currently employed.

    With current approaches to create ingredients from an appropriate source, the material with the target compound or molecule in it is soaked in a solvent, heated, and then over the course of several hours the desired ingredient diffuses into the solvent. After filtration, drying, and other processing, that ingredient is finally isolated and then collected.

    It works, but it’s far from ideal. Aside from the fact that this technique doesn’t work very well at large scale, yields are relatively low. Worse, many undesirable components can still be found in the extract, lowering the quality and purity of the ingredient.

    Radient Technologies uses an ingredient-extraction process called microwave assisted processing, or “MAP,” for short.

    Using its patented MAP process, Radient is able to selectiv

  • [By Jim Robertson]

    Small cap Radient Technologies (CVE: RTI) is focused on extracting, isolating and purifying food/nutraceutical ingredients (colourings, flavourings, preservatives etc) and pharmaceutical raw materials from its20,000 square foot manufacturing plant in Edmonton, Alberta. The Companyworks with global brands across a range of industries (including Food and Beverage, Nutrition and Supplements, Pharmaceuticals, Personal Care and Cosmetics and Biofuel) andengageswithits clients in three distinct phases:

  • [By Matthew Briar]

    Although the past several years have been very good ones for the cannabis — marijuana and hemp — industry, it’s still mostly being done in an old, artisan-style fashion. Most companies haven’t figured out a way of scaling up their outputs by improving their operating/production efficiency, even though the market’s growth has merited. Radient Technologies Inc (CVE:RTI) represents that next evolution of the cannabinoid business, introducing a new approach to extracting cannabinoids from cannabis plants that will not only improve yields, but create a superior, purer product.

    Canada-based Radient Technologies has developed — and patented – an ingredient-extraction process called microwave assisted processing, or “MAP,” for short. As the name implies, the use of radio microwaves helps the extraction process along. To fully appreciate why it matters, however, one has look at the approach other ingredients suppliers are utilizing now.

    With current approaches to create ingredients from an appropriate source, the material with the target compound or molecule in it is soaked in a solvent, heated to 50 degrees Celsius (or more), and over the course of several hours, the desired ingredient diffuses into the solvent. After filtration, drying, and other processing, that ingredient is finally isolated and then collected.

    It works, but it’s hardly ideal. Aside from the fact that this technique doesn’t work very well at large scale, yields are relatively low. Worse, a lot of things you don’t want to extract can still be found in the extract, lowering the quality and purity of the ingredient.

    Radient Technologies’ microwave assisted processing changes all of this.

    Using its patented MAP process, Radient is able to selectively deposit microwave energy into a biomass (source material) and heat the target elements while leaving other materials in the mix unaltered. The near-instantaneous “in-core” heating that occurs creates pressure which

good stocks to buy: ADTRAN Inc.(ADTN)

Advisors’ Opinion:

  • [By Monica Gerson]

    ADTRAN, Inc. (NASDAQ: ADTN) is projected to post its quarterly earnings at $0.08 per share on revenue of $141.07 million.

    Layne Christensen Company (NASDAQ: LAYN) is estimated to post a quarterly loss at $0.35 per share on revenue of $156.10 million.

  • [By Monica Gerson]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday’s regular session.

good stocks to buy: QLT Inc.(QLTI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Tuesday afternoon, healthcare shares gained by 0.61 percent. Meanwhile, top gainers in the sector included Kindred Healthcare, Inc. (NYSE: KND), and QLT Inc. (USA) (NASDAQ: QLTI).

Hot Casino Stocks To Own For 2017

It’s not blatantly observable anywhere. But, for anyone willing to connect the dots and do the digging in several places, the message is clear — there’s a huge and fast-growing need for more information technology workers, and that plays right into the hand Staffing 360 Solutions Inc (NASDAQ:STAF) is holding.

There are several data nuggets that point in the same direction, but perhaps none as telling as the recent finding from technology research outfit IDC, which found that by the end of 2017, two-thirds of the CEOs of Global 2000 companies will have digital transformation at the center of their corporate strategies. How are they going to make that happen? Deloitte recently posted some research of its own that should shed some light on the idea. The giant accounting form observed that “In order to maintain the competitive pace of innovation, companies find themselves engaged in a global war for talent.”

Hot Casino Stocks To Own For 2017: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By Todd Campbell]

    The company is also going to continue early stage research into its CAR-T program, including its work on bb2121, a BCMA-targeting therapy that’s being developed with Celgene (NASDAQ:CELG) for multiple myeloma.

  • [By WWW.THESTREET.COM]

    Position: Long GLD small, bonds, SDS; short TLT small, SPY small .

  • [By JACK HOUGH]

    Celgene’s main risk is a little like AMC’s zombies. It will generate more than 60% of its revenue this year from a single medicine called Revlimid, used primarily to treat a type of cancer called multiple myeloma. But Revlimid is gaining regulatory approval for an expanding number of uses. It has plenty of growth potential overseas, and shows promise in combination therapies. And it has more than a decade of remaining patent protection. Analysts predict double-digit yearly revenue growth for Revlimid through the end of the decade.

    By then, Celgene is expected to have four drugs with yearly sales in the billions of dollars, versus just Revlimid today. And a robust pipeline of medicines in development provides ample opportunity for new successes. Management has set a goal of $21 billion in yearly revenue by 2020, up from a projected $9.2 billion this year. If it’s successful, two things are likely to happen. First, Revlimid’s contribution is likely to drop below half of revenue by then. Second, earnings per share could more than double, as Celgene’s growing size offers better leverage on its research and marketing expenses. Shares sell for 22 times this year’s earnings consensus—inexpensive considering the growth outlook.  

  • [By Chris Lange]

    Celgene Corp. (NASDAQ: CELG) short interest for this settlement date increased to 9.97 million shares from the previous 9.26 million. Shares closed most recently at $121.06, in a 52-week range of $93.05 to $127.00.

  • [By Peter Graham]

    A long term performance shows shares of small cap cancer stocks Juno Therapeutics and Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) underperforming whileKite Pharma Inc (NASDAQ: KITE)andlarge cap Celgene Corporation (NASDAQ: CELG) have performed better:

  • [By Ben Levisohn]

    After years of rising and falling in tandem, the biotech sector is all about stock picking now. Credit Suisse analyst Alethia Young and team, for instance, upgraded Regeneron Pharmaceuticals (REGN), and added Celgene (CELG) to its Focus List today. But Amgen (AMGN) wasn’t so lucky as Young cut it to Neutral from Outperform. She explains why:

Hot Casino Stocks To Own For 2017: Roche Holding AG (RHHBY)

Advisors’ Opinion:

  • [By Ben Levisohn]

    We expect a strong 2017 performance from Keytruda in NSCLC, though revenue and EPS estimates are now 2%-7% and 5%-12% below consensus between 2017E-20E. We also expect further pressure on Keytruda in 2018, driven by share losses in first-line non-small cell lung cancer to Bristol-Myers Squibb (BMY), AstraZeneca (AZN) and Roche (RHHBY) as well as an increasing overhang from the Januvia/ Janumet patent expiries as they loom ever closer. Merck screens poorly on many valuation metrics to us and we have downgraded the shares to Underperform.

  • [By SEEKINGALPHA.COM]

    As with INCY, the focus of Regeneron (NASDAQ:REGN) is cutting-edge science to produce superior molecules that have limited competition. Its flagship drug Eylea took on and defeated the incumbent, Lucentis from Roche (OTCQX:RHHBY), by having both a longer activity leading to less frequent injections into the eye and an additional mechanism of action. This provides it partial insulation from pricing pressures; and, REGN has never taken a price increase on Eylea, which has been on the market since late 2011. Eylea is now selling $5 B globally, a number that is rising and that I believe exceeds the pace set by Revlimid and almost every other drug in history (inflation not accounted for, though).

  • [By SEEKINGALPHA.COM]

    As the graphic below shows, ImmunoGen’s product pipeline is potentially significant. Furthermore, it is impressive to see the involvement and partnerships in these early stage compounds by some of the world’s leading pharmaceutical and biotech companies. This includes firms like Amgen (NASDAQ:AMGN), Roche (OTCQX:RHHBY), Bayer (OTCPK:BAYRY), Sanofi (NYSE:SNY), Eli Lilly (NYSE:LLY), and Novartis (NYSE:NVS).

  • [By SEEKINGALPHA.COM]

    Current biologic top sellers in RA include AbbVie (NYSE:ABBV), Johnson & Johnson (NYSE:JNJ), Amgen (NASDAQ:AMGN), Pfizer (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Roche (OTCQX:RHHBY), and UCB (OTCPK:UCBJF). The table below shows the drugs marketed by these pharmaceutical giants and relevant details:

  • [By SEEKINGALPHA.COM]

    There’s still a lot to love about BMY and Opdivo, as they have the potential to be much larger. Now, notable BMY buyers could be the likes of Novartis (NYSE:NVS), Roche (OTCQX:RHHBY) or Pfizer (NYSE:PFE) – PFE has been looking to up its presence in the oncology market, and is also looking for a major purchase. BMY has a strong oncology pipeline that could work well with PFE or even Gilead (NASDAQ:GILD). GILD has an interest in oncology, and has plenty of cash for a buyout.

Hot Casino Stocks To Own For 2017: Frontier Communications Corporation(FTR)

Advisors’ Opinion:

  • [By Paul Ausick]

    Frontier Communications Inc. (NASDAQ: FTR) posted a new 52-week low of $2.31 on Wednesday, down about 4.1% compared with Tuesday’s closing price of $2.41. The stock’s 52-week high is $5.75. Volume was more than double the daily average of around 28 million shares. The company had no specific news today, but the dividend yield rose nearly another full point to 16.6% on Wednesday.

  • [By Ben Levisohn]

    Frontier Communications (FTR) sunk to the bottom of the S&P 500 today.

    Getty Images

    Frontier Communicationsdropped 4.7% to $2.41, while the S&P 500 declined 0.3% to 2,365.45.

    Why did Frontier sink today? There’s no news that I’ve been able to find, so let’s blame the Federal Reserve, which is widely expected to hike interest rates tomorrow. Frontier is primarily known for paying a hefty dividend–it now tops 17%–and dividends tend to fall out of favor when interest rates rise. (Utilities, however, dropped just 0.1% today, so maybe that theory is bunk.)

    Frontier Communications was the biggest loser last week when it dropped 5.1% after getting cut toNeutral from Buy at BofA Merrill Lynch. It was a string of events that began with Frontier’s earnings on Feb. 28, earnings that led Wells Fargo to opine that the company was still a “show me story.”

    Frontier Communications’ market capitalization fell to $2.8 billion today from $3 billion yesterday. It reported a net lossof $376 million on sales of $8.9 billion in 2016.

  • [By Ben Levisohn]

    Frontier Communications (FTR) tumbled to the bottom of the S&P 500 today after getting cut to Neutral from Buy at BofA Merrill Lynch.

    Agence France-Presse/Getty Images

    Frontier Communicationsdropped 5.1% to $2.62, while the S&P 500 declined 0.3% to 2,368.38.

    24/7 Wall St.’sJon C. Ogg excerpts from Merrill Lynch’s note:

    In our view, the challenge for the stock is that as the top line has compressed at a surprising rate, the payout ratio and therefore risk to the dividend, is rising. With a 15% yield already, we see the stock as caught in a negative feedback loop. The market is pricing in a dividend cut that neednt happen now or even in the next several years, but the mere fact the yield is that high carries the risk that the Board and management could simply respond to the market by trimming the dividend proactively Even if the dividend were cut 50%, we dont believe there would be substantial downside for the stock as the yield would emerge at a relatively more normal 7.5%. Until FTR can show business stability, however, which we had expected in 4Q but now do not expect until 2H at the earliest, irrespective of the attractive yield, we dont believe the stock will be able to outperform.

    Frontier Communications’ market capitalization fell to $3.1 billion today from $3.2 billion yesterday. It reported a net loss of $376 million on sales of $9 billion in 2016.

  • [By Lisa Levin]

    Telecommunications services shares climbed 0.56 percent in trading on Thursday. Meanwhile, top gainers in the sector included Frontier Communications Corp (NASDAQ: FTR), and 8×8, Inc. (NASDAQ: EGHT).

  • [By Paul Ausick]

    Frontier Communications Corp. (NASDAQ: FTR) dropped about 6.9% on Tuesday to record a new 52-week low of $2.57 against a high of $5.77. The stock closed at $2.76 on Monday. Volume was more than double the daily average of around 25 million shares. The company had no specific news Tuesday, but the struggling company is just getting slaughtered.

Hot Casino Stocks To Own For 2017: Safe Bulkers Inc(SB)

Advisors’ Opinion:

  • [By Elizabeth Balboa]

    Meanwhile, Safe Bulkers, Inc. (NYSE: SB) rose $0.73 throughout the 2016, Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) fell $1.69 and Navios Maritime Partners L.P. (NYSE: NMM) dropped $0.93.

Juno Therapeutics Q4 Earnings Report: What to Expect?

The Q4 2016 earnings report of mid cap cancer stock Juno Therapeutics Inc(NASDAQ: JUNO) is scheduled for after the market closes onWednesday (March 1st).Juno Therapeutics was inour SmallCap Network Elite Opportunity (SCN EO) portfolio in the past because thecompanywas well capitalized and had promising novel cellular immunotherapies based platforms (Immunotherapy involves engineering a patient’s cells and then infusing them back into the body to boost the immune system and better fight cancer with less side effects than radiation). A pullbackhad also madesharestechnically attractive for traders at the time.However and last November, Juno Therapeutics lost nearly a quarter of its value after two patients enrolled in its cancer trial died -prompting the Company to place the trial on hold.

A technical chart for small cap Juno Therapeutics shows downtrending lines, but shares have been breaking a bit higher from a December bottom:

A long term performance shows shares of small cap cancer stocks Juno Therapeutics and Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) underperforming whileKite Pharma Inc (NASDAQ: KITE)andlarge cap Celgene Corporation (NASDAQ: CELG) have performed better:

Back in November, Juno Therapeutics reported third quarter revenue of $20.8 million versus $1.6 million due primarily to revenue recognized in connection with the Celgene collaboration and CD19 opt-in. The net losswas $56.9 million versus$23.2 million. Cash, cash equivalents, and marketable securities as of September 30, 2016 were $1.04 billion compared to $1.11 billion as of June 30, 2016 and $1.22 billion as of December 31, 2015. The CEO commented:

JCAR017, a key product candidate of our CD19 platform, has shown encouraging preliminary efficacy and safety results in NHL and pediatric ALL. At the upcoming American Society of Hematology meeting, additional data from our Phase I trial for JCAR017 in NHL patients will be presented. Progress with CAR T therapy continues as we strive to bring these innovative product candidates to patients battling cancer. We look forward to the upcoming presentations at ASH, including 11 total presentations from a number of ongoing and completed studies.

Finally, here is a quick recap ofmid cap Juno Therapeutics recent earnings history along with EPS estimate trends from the Yahoo! Finance analyst estimates page:

12/31/20153/31/20166/30/20169/30/2016
EPS Est. -0.45 -0.52 -0.41 -0.55
EPS Actual -0.53 -0.78 -0.64 -0.57
Difference -0.08 -0.26 -0.23 -0.02
Surprise % -17.80% -50.00% -56.10% -3.60%
EPS TrendCurrent Qtr. (Dec 2016)Next Qtr. (Mar 2017)Current YearNext Year
Current Estimate -0.61 -0.8 -2.6 -2.82
7 Days Ago -0.61 -0.8 -2.6 -2.82
30 Days Ago -0.63 -0.82 -2.6 -2.84
60 Days Ago -0.63 -0.82 -2.6 -2.84
90 Days Ago -0.62 -0.83 -2.54 -2.72

Do you like this trading idea and want more trading setups delivered to you every day? Consider investing in a subscription to our SmallCap Network Elite Opportunity (SCN EO) portfolio newsletter or our Under the Radar Movers newsletter where you’ll get more and even better trading setups, investing ideas or tips.

money stock market

Note: The following report reflects my personal opinion only. I’ve spent months developing this thesis, but the included valuation targets are purely driven by my opinion of this firm. All investors should always conduct their own full due diligence before making any allocation decisions. Nothing in this report reflects an investment recommendation on behalf of J Mintzmyer nor Mintzmyer Investments LLC. Members of Value Investor’s Edge received a first look at this report.

Overview

The following report reflects my bullish thesis for Teekay Corporation (NYSE:TK), which is my top idea for 2017. I have been developing this thesis and increasing exposure during the past few months as TK’s prospects continue to improve at a steady pace while the share price has languished. The precise timing of this report was spurred by Seeking Alpha’s “Catalyst-Driven” contest.

Our bullish thesis on TK:

TK’s future valuation is nearly 80% dependent on cash flows an d ownership stakes in its two partnership ‘daughter’ firms: Teekay LNG Partners (NYSE:TGP) and Teekay Offshore Partners (NYSE:TOO). When TK traded based on this method of valuation, between 2010 and 2015, the shares traded between $21 and $67. Over the past 11 months, spurred by a dividend cut, TK has been erroneously revalued by virtually all mainstream analysts based on its own limited operating assets. TK stock has recently traded in tight correlation to oil prices, while the vast majority of Teekay Group’s $20B fee-based backlog is not directly related to the current oil pricing.

money stock market: Fox Factory Holding Corp.(FOXF)

Advisors’ Opinion:

  • [By Javier Hasse]

    Fox Factory Holding Corp (NASDAQ: FOXF) was down 1.8 percent after posting a 2.16 percent rise over the day.

    Finally, Groupon Inc (NASDAQ: GRPN) gained 1.3 percent, continuing with the 3.85 percent spike it experienced on Friday trading.

money stock market: Lumber Liquidators Holdings, Inc(LL)

Advisors’ Opinion:

  • [By Monica Gerson]

    Lumber Liquidators Holdings Inc (NYSE: LL) is projected to report a quarterly loss at $0.24 per share on revenue of $237.44 million.

    Fossil Group Inc (NASDAQ: FOSL) is estimated to post its quarterly earnings at $0.15 per share on revenue of $666.60 million.

money stock market: PAR Technology Corporation(PAR)

Advisors’ Opinion:

  • [By Lisa Levin]

    On Tuesday, technology shares gained by 1.61 percent. Meanwhile, top gainers in the sector included Himax Technologies, Inc. (ADR) (NASDAQ: HIMX), up 13 percent, and PAR Technology Corporation (NYSE: PAR), up 9 percent.

  • [By Lisa Levin]

    PAR Technology Corporation (NYSE: PAR) shares were also up, gaining 15 percent to $6.59. Par Technology reported Q4 adjusted earnings of $0.13 per share on revenue of $56.8 million.

money stock market: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Reports suggest that Gilead Sciences (GILD) and Celgene (CELG) have joined the bidding process forMedivation (MDVN), one that already includes (maybe) Amgen (AMGN), and of course Sanofi (SNY), which is trying to throw out Medivation’s board. Of the three biotech giants, Citigroup’s Robyn Karnauskas and team argue that Amgen is best positioned to win the battle. They explain why:

  • [By Teresa Rivas]

    Celgene (CELG) is rising on Thursday, on the heels of its mixed first quarter earnings report.

    F. Martin Ramin for WSJ. Magazine, Styling by Anne Cardenas

    Celgene said it earned $1.32 a share on revenue of $2.51 billion. Analysts were looking for earnings of $1.27 a share on revenue of $2.58 billion.

    For the full year, the company said it expects to earn between $5.60 and $5.70 a share, compared to the $5.68 consensus estimate. For fiscal 2017, it lowered its forecast, saying it now expects to earn between $6.75 and $7 a share (from a previous $7.25), compared to the $7.21 consensus.

    Raymond Jamess Christopher Raymond reiterated a Strong Buy rating; he writes that the lower 2017 guidance wasnt really a surprise, and the 2020 numbers still look encouraging:

    Recall, management had suggested a 2017 guidance update would arrive at the 1Q16 call, with an ~$800 million FX headwind that has surfaced since its original issuance. Today, FY17 product revenue guidance was lowered to $12.7-13.0 billion (previously $13-14 billion), which brackets pre-existing FY17 consensus of $12.954 billion. Revlimid net sales moves up $1 billion to $8 billion and Abraxane was lowered to $1 billion (previously $1.5-2.0 billion). Non-GAAP EPS moves to $6.75-7.00 from $7.25 (consensus $7.20). Separately, 2020 targets remain in place. Bottom line, the guidance update should surprise few in our view, and will likely be seen as a clearing event.

    SunTrust Robinson Humphreys Yatin Suneja reiterated a Buy rating, and also wasnt concerned by the guidance:

    Though 1Q tends to be seasonally weak due to Medicare donut hole payments and higher gross-to-net adjustments, Celgene had a better start to 1Q with revenues up 21% Y/Y (vs. 18-19% historically in 1Q). Revlimid 1Q sales (+17% Y/Y) were slightly above expectations. While Pomalyst did OK in the U.S., sales were down in ROW. As expected Abraxane had a rough start to the year, leading to

  • [By Ben Levisohn]

    BMO Capital Markets analyst M. IanSomaiya and team take a look at the “clinical readouts through the end of 2016″ and find upside catalysts for Celgene (CELG), Amgen (AMGN), Biogen (BIIB), and Gilead Sciences (GILD) They explain:

  • [By Ben Levisohn]

    Catalysts remain significant for the biotech industry: The biotech industry
    obviously remains open to swings given the political landscape. That said,
    fundamental catalysts for new drugs are also beginning to favor biotech again
    with PCSK9 outcomes studies, new drug launches from Regeneron (REGN), Amgen (AMGN) and Biogen (BIIB) possible in 2017 and key PhIII readouts for Celgene (CELG) and Incyte (INCY) in 2017.

  • [By WWW.THESTREET.COM]

    Position: Long GLD small, bonds, SDS; short TLT small, SPY small .